Projet INSPIRE (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during clinical development and beyond. This indicates current SP screens fail to detect a number of (late-onset) functional or structural CV toxicities. Additionally, SP uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3Rs. The vision of INSPIRE is to advance and “inspire” SP by exploring new technological capabilities (WP1), addressing emerging CV concerns (WP2) and delivering new validated solutions for CV safety screening (WP3). To this end, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) in vitro humanized cardiomyocytes assays, ii) unparalleled in vivo hardware/software solutions, iii) in silico predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators. Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme (WP4) with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic ever-changing industry.

Mots clés : safety pharmacology, cardiovascular toxicity, cardio oncology

Participants :
- Tse systems gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 252788.4 €
- UCB Pharma (Belgium) (Belgique) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 256320.0 €
- Notocord systems (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 549604.08 €
- Institut national de recherche en sciences et technologies du numérique (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- University of Nottingham (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €
- University of Antwerp (Belgique) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 768960.0 €
- Maastricht University (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 531239.76 €
- Ncardia bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Weizmann Institute of Science (Israël) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263500.92 €
- Boehringer Ingelheim (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 252788.4 €
- Ncardia services bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 265619.88 €